Keros Therapeutics (Keros Therapeutics) Long-Term Capital Lease Obligation : $13.44 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics Long-Term Capital Lease Obligation?

Keros Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.44 Mil.

Keros Therapeutics's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($13.95 Mil) to Sep. 2023 ($13.70 Mil) and declined from Sep. 2023 ($13.70 Mil) to Dec. 2023 ($13.44 Mil).

Keros Therapeutics's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($12.81 Mil) and increased from Dec. 2022 ($12.81 Mil) to Dec. 2023 ($13.44 Mil).

Keros Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Keros Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics Long-Term Capital Lease Obligation Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.90

0.48

0.23

12.81

13.44

Keros Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															12.81	13.99	13.95	13.70	13.44

Keros Therapeutics (NAS:KROS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Keros Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Keros Therapeutics (Keros Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website

https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Executives

Keith Regnante	officer: Chief Financial Officer	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey	officer: Chief Scientific Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi	officer: Chief Operating Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles	director	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Tomer Kariv	director, 10 percent owner	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Ran Nussbaum	director, 10 percent owner	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jasbir Seehra	director, officer: Chief Executive Officer	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Arkin Bio Ventures Limited Partnership	10 percent owner	6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406